Press Releases & Events 2020

All | 2021 | 2020 | 2019 | 2018 | 2017

December 17, 2020

Tessa Therapeutics Appoints David McIntyre as Chief Financial Officer

Mr. McIntyre brings over 25 years of global financial, operational and legal experience, including over 10 years as Chief Financial Officer of various publicly listed and privately held entities.

August 6, 2020

Tessa Therapeutics Announces Results from Two Independent Phase 1/2 Trials of Autologous CD30 CAR-T Cell Therapy in Patients with Relapsed or Refractory Hodgkin Lymphoma

Tessa Therapeutics today announced the publication of results in the Journal of Clinical Oncology from two investigator-sponsored Phase 1/2 trials led by Baylor College of Medicine and the University of North Carolina Lineberger Comprehensive Cancer Center.

May 5, 2020

Tessa Therapeutics Announces New Executive Leadership

Tessa Therapeutics today announced that Jeffrey H. Buchalter will assume the role of Chief Executive Officer, and Göran A. Ando will become Chairman of the Board, with immediate effect.

February 27, 2020

Tessa Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to its CD30 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory CD30-positive Classical Hodgkin Lymphoma

RMAT designation follows positive proof-of-concept data from two independent Phase I/II clinical studies conducted by Baylor College of Medicine and University of North Carolina Lineberger Comprehensive Cancer Center for the autologous T cell therapy